The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, CHEK2, PALB2, RAD51D, FANCA, EPCAM. The trial involves a screening MRI of the prostate every two years and a biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests. For more details and contact information, please contact Anna Couvillon, NP at email@example.com, +1 240 858-3148, and/or NCT03805919.